During the last session, Bicara Therapeutics Inc (NASDAQ:BCAX)’s traded shares were 0.58 million. At the end of the trading day, the stock’s price was $9.32, reflecting an intraday loss of -1.17% or -$0.11. The 52-week high for the BCAX share is $28.09, that puts it down -201.39 from that peak though still a striking 16.31% gain since the share price plummeted to a 52-week low of $7.80. The company’s market capitalization is $508.28M, and the average trade volume was 819.21K shares over the past three months.

Bicara Therapeutics Inc (NASDAQ:BCAX) trade information

Bicara Therapeutics Inc (BCAX) registered a -1.17% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.17% in intraday trading to $9.32, hitting a weekly high. The stock’s 5-day price performance is -19.45%, and it has moved by -38.03% in 30 days.

The consensus price target of analysts on Wall Street is $28, which implies an increase of 66.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $48 respectively. As a result, BCAX is trading at a discount of -415.02% off the target high and 14.16% off the low.

While earnings are projected to return 42.88% in 2025, the next five years will return 11.95% per annum.

BCAX Dividends

Bicara Therapeutics Inc is due to release its next quarterly earnings on 2025-May-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Bicara Therapeutics Inc (NASDAQ:BCAX)’s Major holders

Bicara Therapeutics Inc insiders own 11.65% of total outstanding shares while institutional holders control 89.28%, with the float percentage being 101.05%.